Skip to main content
SpringerLink
Log in

Long-Term Treatment of Focal Dystonias (Cervical and Writer’s Cramp): Clinical and Quality of Life Impact

  • Chapter
Dystonia and Dystonic Syndromes

Abstract

Dystonias are a group of disorders with many different clinical manifestations but with certain common features. Affected patients share involuntary sustained or intermittent muscle contractions that cause abnormal postures and/or repetitive movements. The most common forms of adult-onset focal dystonias are cervical dystonia, blepharospasm, oromandibular dystonia, laryngeal dystonia, and limb dystonias such as writer’s cramp. In this chapter, we were interested in certain aspects of the long-term treatment of two focal dystonias, cervical dystonia and limb dystonia (writer’s cramp), with botulinum toxin A (BoNT-A).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fahn S. Concept and classification of dystonia. Adv Neurol. 1988;50:1–8.

    Article  CAS  PubMed  Google Scholar 

  2. Singer C, Velickovic M. Cervical dystonia: etiology and pathophysiology. Neurol Clin. 2008;26 Suppl 1:9–22.

    Article  PubMed  Google Scholar 

  3. Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008;26 Suppl 1:43–53.

    Article  PubMed  Google Scholar 

  4. Kaňovský P, Streitová H, Bareš M, Hortová H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long lasting effect. Mov Disord. 1999;14(5):886–8.

    Article  PubMed  Google Scholar 

  5. Kaňovský P, Bareš M, Streitová H, Klajblová H, Daniel P, Rektor I. Abnormalities of cortical excitability and cortical inhibition in cervical dystonia. Evidence from somatosensory evoked potentials and paired transcranial magnetic stimulation. J Neurol. 2003;250:42–50.

    Article  PubMed  Google Scholar 

  6. Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord. 2004;19:1054–9.

    Article  PubMed  Google Scholar 

  7. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2:245–7.

    Article  CAS  PubMed  Google Scholar 

  8. O’Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O’Neil T, Factor S, Seeberger L. Cervical dystonia severity scale reliability study. Mov Disord. 2001;16:1086–90.

    Article  PubMed  Google Scholar 

  9. Sheehy MP, Rothwell JC, Marsden CD. Writer’s cramp. Adv Neurol. 1988;50:457–72.

    CAS  PubMed  Google Scholar 

  10. Dashtipour K, Pender RA. Evidence for the effectiveness of botulinum toxin for writer’s cramp. J Neural Transm. 2008;115:653–6.

    Article  CAS  PubMed  Google Scholar 

  11. Karp BI. Limb dystonia. In: Stacy MA, editor. Handbook of dystonia. New York: Informa Healthcare; 2007. p. 155–77.

    Google Scholar 

  12. Pearce JMS. A note on scrivener’s palsy. J Neurol Neurosurg Psychiatry. 2005;76:513.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Bell C. Partial paralysis of the muscles of the extremities. The nervous system of the human body. London: Taylor and Francis; 1833. p. 57–8.

    Google Scholar 

  14. Marsden CD, Sheehy MP. Writer’s cramp. Trends Neurosci. 1990;13(4):148–53.

    Article  CAS  PubMed  Google Scholar 

  15. Jedynak PC, Tranchant C, de Beyl DZ. Prospective clinical study of writer’s cramp. Mov Disord. 2001;16:494–9.

    Article  CAS  PubMed  Google Scholar 

  16. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247:787–92.

    Article  Google Scholar 

  17. Butler AG, Duffey PO, Hawthorne MR, Barnes MP. An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years. Adv Neurol. 2004;94:95–9.

    PubMed  Google Scholar 

  18. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton 3rd LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988;3:188–1894.

    Article  CAS  PubMed  Google Scholar 

  19. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Das CP, Prabhakar S, Truong D. Clinical profile of various sub-types of writer’s cramp. Parkinsonism Relat Disord. 2007;10:1016.

    Google Scholar 

  21. Sheehy MP, Marsden CD. Writers’ cramp–a focal dystonia. Brain. 1982;105(Part 3):461–80.

    Article  PubMed  Google Scholar 

  22. Zeuner KE, Shill HA, Sohn YH, Molloy FM, Thornton BC, Dambrosia JM, Hallett M. Motor training as treatment in focal hand dystonia. Mov Disord. 2005;20(3):335–41.

    Article  PubMed  Google Scholar 

  23. Streitova H, Bares M. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg. 2014;114(4):285–91.

    Article  PubMed  Google Scholar 

  24. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699–706.

    Google Scholar 

  25. Haussermann P, Marczoch P, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord. 2004;19:303–8.

    Article  PubMed  Google Scholar 

  26. Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol. 2005;12(3):163–70.

    Article  CAS  PubMed  Google Scholar 

  27. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20:592–7.

    Article  PubMed  Google Scholar 

  28. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009;31(5):463–6.

    Article  CAS  PubMed  Google Scholar 

  29. Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E. A 17-year experience of abobotulinumtoxin A in cervical dystonia. Int J Neurosci. 2012;122:354–7.

    Article  CAS  PubMed  Google Scholar 

  30. Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249–66.

    Article  CAS  Google Scholar 

  31. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–60.

    Article  PubMed  Google Scholar 

  32. Cohen LG, Hallett M, Geller BD, Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1989;52:355–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Abbruzzese G, Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotox Res. 2006;9:109–14.

    Article  CAS  PubMed  Google Scholar 

  34. Valls-Sole J, Tolosa ES, Ribera G. Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry. 1991;54:310–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Trompetto C, Curra A, Buccolieri A, et al. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord. 2006;21:777–82.

    Article  PubMed  Google Scholar 

  36. Karp BI. Botulinum toxin treatment of occupational and focal hand dystonia. Mov Disord. 2004;(Suppl 8):S116–9.

    Google Scholar 

  37. Albanese A, Barnes AP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Sole J. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13:433–44.

    Article  CAS  PubMed  Google Scholar 

  38. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 1990;53:640–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Djebbari R, du Montcel ST, Sangla S, Vidal JS, Gallouedec G, Vidailhet M. Factors predicting improvement in motor disability in writer’s cramp treated with botulinum toxin. J Neurol Neurosurg Psychiatry. 2004;75(12):1688–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Hsiung GY, Das SK, Ranawaya R. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10 years period. Mov Disord. 2002;17:1288–93.

    Article  PubMed  Google Scholar 

  41. Turjanski N, Pirtosek Z, Quirk J. Botulinum toxin in the treatment of writer’s cramp. Clin Neuropharmacol. 1996;19:314–20.

    Article  CAS  PubMed  Google Scholar 

  42. Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology. 1994;44:70–6.

    Article  CAS  PubMed  Google Scholar 

  43. Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011;26(4):750–3.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Mari Z, Bruno M, Lee B, Karp BI, Hallett M. Long-term botulinum toxin treatment for focal hand dystonia. Neurology. 2004;62(7, Suppl 5):A512.

    Google Scholar 

  45. Ranoux D, Gury C. Practical handbook on botulinum toxin. Marseille: Solal Editeurs; 2007.

    Google Scholar 

  46. Dressler D. Botulinum toxin therapy. Stuttgart/New York: Thieme-Verlag; 2000.

    Google Scholar 

  47. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71(2):193–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia A double-blind, placebo-controlled study. Neurology. 1987;37:616–23.

    Article  CAS  PubMed  Google Scholar 

  49. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213–8.

    Article  CAS  PubMed  Google Scholar 

  50. Wissel J, Kaňovský P, Růžička E, Bareš M, Hortová H, Streitová H, Jech R, Roth J, Brenneis C, Müller J, Schnider P, Auff E, Richardson A, Poewe W. Efficacy and safety of a standardised 500 unit of Dysport® (clostridium botulinum type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248(12):1073–8.

    Article  CAS  PubMed  Google Scholar 

  51. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxin A in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35:208–14.

    Article  CAS  PubMed  Google Scholar 

  52. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9(2–3):145–8.

    Article  CAS  PubMed  Google Scholar 

  53. Vogt T, Lüssi F, Paul A, Urban P. Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt. 2008;79(8):912–7.

    Article  CAS  PubMed  Google Scholar 

  54. Kessler KR, Skuta M, Benecke R. for German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol. 1999;246:265–74.

    Google Scholar 

  55. Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm. 2009;116(4):437–41.

    Article  CAS  PubMed  Google Scholar 

  56. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316–23.

    Article  PubMed  Google Scholar 

  57. Gill CE, Manus ND, Pelster MW, Cook JA, Molinari AL, Charles D. Continuation of long-term care for cervical dystonia at an Academic Movement Disorders Clinic. Toxins (Basel). 2014;5:776–83.

    Article  Google Scholar 

  58. Kaňovský P, Bareš M, Streitová H, Pospíšilová D, Dufek M. Socioeconomic aspects of the treatment of facial dyskinesias with botulinum toxin A. Czech Slov Neurol Neurochir. 1996;59/92(3):148–51.

    Google Scholar 

  59. Skogseid IM, Røislien J, Claussen B, Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord. 2005;20(12):1604–9.

    Article  PubMed  Google Scholar 

  60. Jinnah HA, Berardelli A, Comella C, DeFazio G, DeLong MR, Factor S, Galpern WR, Hallett M, Ludlow CL, Perlmutter JS, Rosen AM. for the Dystonia Coalition Investigators. The focal dystonias: current views and challenges for future research. Mov Disord. 2013;28(7):926–43.

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Ministry of Health of the Czech Republic/the Ministry of Health Departmental Research and Development Programme III (2010–2015) NT/13437 and by the “CEITEC – Central European Institute of Technology” project (CZ.1.05/1.1.00/02.0068) from the European Regional Development Fund.

We wish to express our thanks to Ing. Zdenek Novotny for the statistical analysis and to Anne Johnson for grammatical assistance.

We would like to thank our colleagues who treated and followed some of the patients, Petr Kaňovský, Hana Klajblová, Dagmar Kubová, Eduard Minks, Igor Nestrašil, Jiří Pulkrábek, Irena Rektorová, Silvie Sedláčková, Martina Bočková, Hana Streitová, and Jiří Zicha; our nursing staff, Vlasta Dírerová, Anita Hlučková, Jana Bártová, and Petra Krainerová; and Ludmila Vápeníková, who helped with part of the patient database.

Author information

Authors and Affiliations

  1. 1st Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic

    Martin Bareš MD, PhD & Pavel Filip

  2. Behavioural and Social Neuroscience Research Group, CEITEC – Central European Institute of Technology, Masaryk University, Brno, Czech Republic

    Martin Bareš MD, PhD & Pavel Filip

  3. 1st Department of Neurology, Faculty of Medicine, St. Anne’s University Hospital, Masaryk University Medical School, Brno, Czech Republic

    Marek Baláž

  4. Multimodal and Functional Imaging Research Group, CEITEC – Central European Institute of Technology, Masaryk University, Brno, Czech Republic

    Marek Baláž

Authors
  1. Martin Bareš MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marek Baláž
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pavel Filip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Bareš MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Neurology, Palacky University Medical School University Hospital Olomouc, Olomouc, Czech Republic

    Petr Kanovsky

  2. Sobell Department of Motor Neuroscience and Movement Disorders, University College London Institute of Neurology, London, United Kingdom

    Kailash P. Bhatia

  3. Department of Neurology and Psychiatry, The Royal and Pontifical University of Santo Tomas, Manila, Philippines

    Raymond L. Rosales

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Wien

About this chapter

Cite this chapter

Bareš, M., Baláž, M., Filip, P. (2015). Long-Term Treatment of Focal Dystonias (Cervical and Writer’s Cramp): Clinical and Quality of Life Impact. In: Kanovsky, P., Bhatia, K., Rosales, R. (eds) Dystonia and Dystonic Syndromes. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1516-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1516-9_11

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1515-2

  • Online ISBN: 978-3-7091-1516-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation